Shanghai Sinobioway Sunterra Biotechnology

Shanghai Sinobioway Sunterra Biotechnology focuses on cutting-edge biotechnology, specifically in the field of adoptive cellular therapies. It was formed by Sinobioway Group, Sunterra Capital, and F1 Oncology for the express purpose of developing novel CAB-CAR-T therapies for solid tumor malignancies in China. SSSB's GMP cell processing facilities in Shanghai have been developed to support clinical research through key academic collaborations.

Wu Zili

Director and Founder

1 past transactions

Exuma Biotech

Venture Round in 2018
Exuma Biotech is a clinical-stage biotechnology company focused on discovering and developing adoptive cellular therapies for solid tumors and hematological malignancies. Established in 2015 and headquartered in West Palm Beach, Florida, with additional locations in San Diego, California, Grand Cayman, and Shanghai, Exuma Biotech specializes in chimeric antigen receptor-T cell (CAR-T) therapy. The company aims to enhance the immune system's ability to combat various solid tumor malignancies, including renal cell carcinoma, soft tissue sarcoma, and gastric cancer. Through its logic-gated CAR-T platform, Exuma Biotech seeks to improve patient access to innovative cell and gene therapies. The company has formed strategic partnerships to advance its research and development efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.